ASPIRIN; METHOCARBAMOL: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Stevens J	METHOCARBAMOL AND ASPIRIN	aspirin; methocarbamol	TABLET;ORAL	081145	ANDA	Jerome Stevens Pharmaceuticals, Inc.	50564-490-01	100 TABLET in 1 BOTTLE (50564-490-01)	1995-01-31
Stevens J	METHOCARBAMOL AND ASPIRIN	aspirin; methocarbamol	TABLET;ORAL	081145	ANDA	Jerome Stevens Pharmaceuticals, Inc.	50564-490-05	500 TABLET in 1 BOTTLE (50564-490-05)	1995-01-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

In the global pharmaceutical supply chain, sourcing reliable and compliant suppliers for active pharmaceutical ingredients (APIs) like aspirin and methocarbamol remains pivotal for manufacturers, regulators, and healthcare providers. As the demand for these medications persists, understanding the supplier landscape—including regional concentration, manufacturing quality, regulatory adherence, and market dynamics—is essential for strategic procurement and risk mitigation.

Aspirin: An Enduring Analgesic and Antipyretic

Overview

Aspirin, chemically known as acetylsalicylic acid, was first synthesized in the late 19th century and remains one of the most widely used NSAIDs globally. Its synthesis widely involves salicylic acid derivatives, with production concentrated mainly in regions with established chemical manufacturing capabilities.

Major Suppliers and Manufacturing Hubs

India: Dominates the aspirin market, supplying approximately 70-80% of the world's APIs, supported by a large number of WHO-GMP compliant facilities. Companies like Gufic Biosciences, Sun Pharma, and Aarti Drugs are prominent.
China: Hosts several integrated chemical and pharmaceutical manufacturers, with firms such as Huanghua Silang Chemical, producing both APIs and intermediates, contributing significantly to global supplies.
European and U.S. Suppliers: Generally produce finished formulations rather than APIs. Leading companies include Bayer and Johnson & Johnson, which predominantly focus on branded and generic formulations in regulated markets.

Regulatory and Quality Considerations

The strict compliance with Good Manufacturing Practices (GMP) is vital. Indian and Chinese suppliers have made notable advancements in certifying their facilities per WHO, EU, and U.S. FDA standards, though due diligence is recommended (especially for imports). The US FDA, EMA, and WHO prequalification programs serve as benchmarks for supplier quality assurance.

Market Dynamics

The generic aspirin market has stabilized due to low entry barriers. Supply chain disruptions, especially during global crises, have underscored dependency risks on Indian and Chinese sources. Recent trends include consolidation among Indian suppliers to meet international quality standards.

Methocarbamol: A Muscle Relaxant with Niche Market

Overview

Methocarbamol, chemically known as 3-(2-methoxyphenoxy)-1,2-propanediol, is a centrally acting muscle relaxant used primarily in pain management and spasticity. Unlike aspirin, it exhibits a more niche manufacturing profile, with supply concentrated among few manufacturers and regions.

Key Suppliers and Manufacturing Regions

India: The primary supplier for methocarbamol APIs. Companies such as Granules India, Alembic Pharmaceuticals, and Cipla produce GMP-compliant APIs and finished products for domestic and international markets.
China: Fewer players manufacture methocarbamol; those involved tend to export primarily to Europe, Asia, and Latin America.
Europe and the U.S.: Limited API production, with some companies producing finished formulations for their markets. Manufacturing often relies on Indian and Chinese APIs.

Regulatory and Compliance Landscape

The supply chain for methocarbamol is less scrutinized compared to more prominent drugs, but quality standards remain critical. Suppliers have increasingly obtained certifications such as DMF (Drug Master File) filings with the FDA and CEP (Certificate of Suitability) from EDQM to facilitate global acceptance.

Market Trends and Challenges

The relatively limited production footprint makes the supply sensitive to regional policy shifts, raw material availability, and manufacturing scale-up challenges. Recent focus on API diversification and quality improvements is observed among Indian producers.

Comparative Analysis of Supplier Strategies

Regionally diversified sourcing: Critical for managing supply risks, especially in volatile geopolitical climates.
Regulatory compliance: Suppliers with proven GMP certification and prequalification enhance supply security.
Quality assurance: Emphasize validated manufacturing processes, traceability, and adherence to international pharmacopeias.
Cost considerations: Indian suppliers offer competitive pricing due to lower manufacturing costs but require prior quality validation.
Environmental and sustainability practices: Increasingly relevant, with suppliers expected to comply with global environmental standards.

Regulatory Trends and Due Diligence

Manufacturers and procurement professionals must prioritize supplier audits, verification of quality certifications, and ongoing monitoring of compliance status. The rapid evolution of GMP standards, especially amid global health crises, underscores the importance of establishing robust qualification programs.

Australian TGA, US FDA, EMA, and WHO maintain stringent oversight and publish guidelines that aid in evaluating supplier compliance. Prequalification programs and third-party audits further enhance supplier reliability.

Supply Chain Risks and Mitigation Strategies

Dependence on single-source suppliers: Increases vulnerability; mitigate by developing multi-sourcing arrangements.
Regional geopolitical tensions: Monitor trade policies and import/export restrictions.
Raw material shortages: Track upstream supply chains for chemicals like salicylic acid, essential in aspirin production.
Regulatory non-compliance: Continuous oversight, supplier qualification, and quality audits mitigate risks.

Conclusion

The supplier landscape for aspirin and methocarbamol reflects a predominantly Indian and Chinese manufacturing footprint, supported by global regulatory standards. Building resilient supply chains involves balancing cost, quality, and compliance considerations while maintaining flexibility through diversified sourcing. Given the vital role of these drugs in clinical practice, proactive supplier management remains critical for healthcare providers and pharmaceutical companies.

Key Takeaways

Indian manufacturers dominate the aspirin API market, providing high-volume, cost-effective options with improving regulatory compliance.
Chinese suppliers contribute significantly to global aspirin supplies, though their regulatory certification levels vary.
Methocarbamol supply is concentrated mainly among Indian producers, with Chinese manufacturers playing a minor role.
Rigorous qualification protocols, including GMP certification and prequalification processes, are essential to ensure supplier reliability.
Supply chain resilience can be substantially enhanced by diversifying sources, continuous compliance monitoring, and strategic inventory management.

FAQs

1. What are the primary considerations when sourcing aspirin APIs?
Safety and compliance are paramount. Ensure suppliers hold GMP certification and are validated by regulatory agencies like the FDA, EMA, or WHO. Cost, lead times, and geographic diversification also influence procurement decisions.

2. How has the COVID-19 pandemic impacted aspirin and methocarbamol supplies?
Disruptions in manufacturing, raw material shortages, and transportation delays have affected supply stability. Indian suppliers, in particular, faced challenges but have generally adapted through increased capacity and quality certifications.

3. Are Chinese suppliers of aspirin and methocarbamol compliant with international standards?
Many Chinese manufacturers have attained WHO-GMP and CE certifications, but due diligence is necessary to verify specific compliance levels, especially for export to stringent markets like the US and Europe.

4. What risks are associated with relying solely on Indian suppliers for these APIs?
Dependence on a single region increases exposure to regulatory, geopolitical, or supply chain disruptions. Establishing multiple sourcing channels mitigates this risk.

5. How can pharmaceutical companies improve supply chain security for these drugs?
Implement multi-sourcing strategies, conduct regular supplier audits, maintain strategic inventory buffers, and stay aligned with international quality standards and regulatory updates.

Sources

[1] GlobalData, "API Market Analysis," 2022.
[2] WHO Prequalification Program, Pharmaceutical Procurement Data, 2022.
[3] US FDA Drug Master Files (DMFs), 2023.
[4] IMS Health, "Pharmaceutical Market Trends," 2022.
[5] Indian Pharmaceutical Alliance, "API Industry Overview," 2022.

Suppliers and packagers for generic pharmaceutical drug: ASPIRIN; METHOCARBAMOL